A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas
Latest Information Update: 04 Nov 2021
At a glance
- Drugs CB 5339 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 04 Jul 2020 Status changed from not yet recruiting to recruiting.
- 01 Jul 2020 Planned initiation date changed from 6th July 2020 to 7th July 2020
- 01 Jul 2020 New trial record